Alembic gets USFDA nod for depression treatment drug


Drug firm Alembic Pharmaceuticals on Friday said it has received approval from the US health regulator for Doxepin Hydrochloride Capsules, used to treat depression and anxiety.

The approved product is therapeutically equivalent to the reference-listed drug product (RLD) Sinequan Capsules of Pfizer Inc.

The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Doxepin Hydrochloride Capsules USP in the strengths of 10 mg, 25 mg, 50 mg, 75 mg and 100 mg, Alembic Pharmaceuticals said in a regulatory filing.

To read more articles on Alembic, click here

Medicine Capsule
Picture: Unsplash

Doxepin Hydrochloride Capsules are recommended for the treatment of psychoneurotic patients with depression and/or anxiety, depression and/or anxiety associated with alcoholism, depression and/or anxiety associated with organic disease and psychotic depressive disorders with associated anxiety including involutional depression and manic-depressive disorders.

Quoting IQVIA data, Alembic Pharma said Doxepin Hydrochloride Capsules USP, 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg have an estimated market size of USD 41 million for twelve months ending December 2020.

Alembic now has a total of 141 ANDA approvals (124 final approvals and 17 tentative approvals) from USFDA.

Also read:

Caplin gets USFDA nod for Neostigmine Methylsulfate Injection

Gilead gets USFDA nod to treat metastatic urothelial cancer

NATCO gets tentative USFDA nod for Ibrutinib tablets

First AI device to help detect colon cancer gets USFDA nod

Aleor gets tentative USFDA nod for drug for topical treatment

Zydus Cadila gets final USFDA nod for drug to treat High…

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon
YouTube Icon

Enter your email address:

Delivered by FeedBurner